Anavex Life Sciences Corp (AVXL)

[XenaLives]

You stated "I just think it became less likely with this poster."

Did you figure in the fact that evidence for current SOC=0 now that the plaque attackers have been outed?

Underlying Pathologies of Alzheimer’s Disease in Patients Treated for More Than Two Years
MARCH 16, 2022 • INVESTOR RELATIONS
ADUHELM continued to reduce two key Alzheimer’s disease pathologies, amyloid beta plaques and p-tau181, in patients treated for up to two and a half years
Data from both Phase 3 studies also show that clinical decline was reduced in participants who had plasma p-tau181 reduction at 78 weeks
These data further inform the scientific evidence for amyloid as a surrogate biomarker and the importance of continuation of treatment

https://investors.biogen.com/news-releases/news-release-details/long-term-phase-3-data-show-aduhelmr-continues-reduce-underlying